Skip to content
CancerIndex

Publication

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.

Authors not recorded

Breast Cancer Res Treat2013PMID 23322234stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23322234
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NCOA3 AMPLIFICATION1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Poor Outcome3accepted
EID492

In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival.

PMID 23322234 · Burandt et al., 2013 · Open in CIViC

civic
NCOA3 OVEREXPRESSION1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Poor Outcome3accepted
EID493

High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival.

PMID 23322234 · Burandt et al., 2013 · Open in CIViC

civic